Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 14/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23508730 | 0.77 | PTPN11 (0.37) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL24879337 | 0.75 | PTPN11 (0.36) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL21653696 | 0.75 | ADORA2A (0.42) | METPTPN11ADORA2AADORA1KDM4E | |
| SCHEMBL16418634 | 0.75 | CA2 (0.38) | ADORA1KDM4ENSD2ALDH1A1MAPT | |
| SCHEMBL26156073 | 0.75 | PTPN11 (0.36) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL21631652 | 0.75 | PTPN11 (0.36) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL21631725 | 0.74 | ADORA2A (0.38) | PTPN11ADORA2AADORA1ALDH1A1MAPT | |
| SCHEMBL28627313 | 0.74 | PTPN11 (0.35) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL29802932 | 0.74 | PTPN11 (0.36) | PTPN11ADORA2AADORA1KDM4ENSD2 | |
| SCHEMBL26920421 | 0.74 | PTPN11 (0.35) | PTPN11ADORA2AADORA1KDM4ENSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002355-A1 | COMPOUND AS SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN7 | MET 311/4885PTPN11 4/4885ADORA2A 4529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.